COMMURE·AI revenue-cycle management (autonomous coding, claims, denials) + ambient clinical documentation + practice-management softwarePrivate

Commure

ConvictionContext

B2B enterprise software with a services-heavy delivery layer; annual subscription by module, reportedly from ~$1M of commitment (Sacra). RCM is paid out of the provider's collected revenue — the correct side of the board's payer test, and the seat Waystar occupies in the listed market. Sold to health systems (HCA, Tenet, Jefferson Health, Providence) and thousands of physician-owned practices, EHR-agnostic across 60+ integrations incl. Epic, Oracle Cerner and MEDITECH. Assembled by M&A: PatientKeeper (from HCA, 2021), Athelas merger (2023), Strongline, Augmedix ($139M, 2024), Memora Health (2024).

Revenue

'More than $200 millionin annual revenue' (SiliconANGLE, 19 Jun 2025); company states ARR 'in the hundreds of millions, has doubled for three consecutive years'; Sacra estimates ~$105M ARR at Mar 2024. Canon CM-PRIV-CM-02 holds absolute ARR UNSOURCED — only the doubling cadence and the volume claims are sourced, and nothing has been published in the fourteen months since.

Rev growth

~+100%/yr claimed to Jun 2025no base disclosed); ~+150% YoY at Mar 2024 (Sacra). Not assertable now — the May 2026 announcement gave customer counts and an automation percentage instead of a growth figure.

Gross margin

Not disclosedand the evidence points below software. Augmedix, the ambient asset Commure bought, had to file: 48.0% GAAP gross margin for FY2023 on $44.9M of revenue (45.1% FY2022, 49.3% Q4 2023). Headcount says the same — 55.7% of ~2,373 staff in Finance and Operations vs 23.8% Engineering, 54.8% in India and Bangladesh (Revelio Labs, Mar 2026 estimate). Legacy RCM is labour arbitrage at 30-45%; software-margin RCM clears 70%+.

Op margin

Not disclosedassumed negative. The only forward statement is cash-flow — positive 'by the end of 2026' (SiliconANGLE) — implying it was not there in mid-2025.

Capex intensity

Low as capexhigh as acquisition spend. Asset-light software plus offshore delivery; inference is opex; Athelas monitoring and Strongline badges are the only hardware.

Valuation

n/aprivate — none exists). Last mark $7B on a $70M round led by General Catalyst with Sequoia, Morgan Stanley and Kirkland & Ellis, 19-20 May 2026. Neither Modern Healthcare's reporting nor any Commure release characterises the mark as pre- or post-money — Commure's own site carries no release for the $70M round — so the qualifier is not asserted here. Either way, $70M setting a $7B headline is ~1% dilution — a negotiated mark from the incumbent owner, not a price at which size clears (the shape of Sword's $40M/$4B).

The read

Where our coverage leans

Coverage leans bearish

Members only

Full financial intelligence for Commure

Earnings, margins & COGS, the income-statement breakdown, SWOT, moats & dependencies, the supplier–customer ecosystem graph, top signals & trends, and the valuation range.

Income statement & margin structure
SWOT, moats & dependency map
Supplier–customer ecosystem graph
Signals, trends & valuation range

See plans

Not financial advice — analyst work product for a qualified professional.